Zdlzodiacal Pharmaceutics Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 17-12-2024
- Paid Up Capital ₹ 2.50 M
as on 17-12-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 29.30%
(FY 2020)
- Profit 37.05%
(FY 2020)
- Ebitda 32.53%
(FY 2020)
- Net Worth 149.80%
(FY 2020)
- Total Assets 25.16%
(FY 2020)
About Zdlzodiacal Pharmaceutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Amar and Anu Amar serve as directors at the Company.
- CIN/LLPIN
U74120UP2015PTC071529
- Company No.
071529
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jun 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Moradabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Zdlzodiacal Pharmaceutics Private Limited offer?
Zdlzodiacal Pharmaceutics Private Limited offers a wide range of products and services, including Psychotherapeutic Agents, Piracetam Syrup, Diclofenac, Diclofenac Sodium Injection, Injectable Products, Nutraceuticals, Allopathic Immunity Booster, Pharmaceutical Medicine, Pharmaceutical Products, Antidepressant & Anti Anxiety Medicines.
Who are the key members and board of directors at Zdlzodiacal Pharmaceutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Amar  | Director | 22-Jun-2015 | Current |
| Anu Amar | Director | 22-Jun-2015 | Current |
Financial Performance of Zdlzodiacal Pharmaceutics.
Zdlzodiacal Pharmaceutics Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 29.3% increase. The company also saw a substantial improvement in profitability, with a 37.05% increase in profit. The company's net worth Soared by an impressive increase of 149.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zdlzodiacal Pharmaceutics?
In 2020, Zdlzodiacal Pharmaceutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zdlzodiacal Pharmaceutics?
Unlock and access historical data on people associated with Zdlzodiacal Pharmaceutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zdlzodiacal Pharmaceutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zdlzodiacal Pharmaceutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
